Clinical Trial Update: Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating perioperative fostamatinib in combination with gemcitabine and nab-paclitaxel for resectable pancreatic ductal adenocarcinoma; currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Fostamatinib (fostamatinib)
• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: University of California, San Diego | Conditions: Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | Status: RECRUITING